Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis

Iversen, Lene Hjerrild; Rasmussen, Peter; Laurberg, Søren

doi:10.1002/bjs.8908

Cited by 122 publications

(103 citation statements)

References 21 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, laparoscopic staging might be helpful for the initial PC workup, especially to determine its form, but has never been assessed for digestive NET [14]. Laparoscopy enables the detection of PC and the evaluation of its extent, even when microscopic involvement is not detectable on conventional imaging, and could prevent nontherapeutic open surgical interventions [17,18]. …”

Section: Evaluation Of Pcmentioning

confidence: 99%

Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors

Mestier¹,

Lardière-Deguelte

Brixi³

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

Well-differentiated digestive neuroendocrine tumors (NET) are a heterogeneous group of neoplasms usually associated with slow growth but a high rate of metastases, including peritoneal carcinomatosis (PC). Herein, we aimed to comprehensively review the current knowledge of PC in terms of implications for the management and prognosis of patients with NET, including the latest studies and expert statements. NET-derived PC concerns about 17% of NET patients and up to 30% of those with small intestine primary NET. It has an independent pejorative prognostic impact. The extent of PC in NET patients and its severity can be expressed by analogy to other malignancies. However, it must be placed in the context of NET disorders, which usually vary from other PC-related malignancies. Recently, a gravity PC score was proposed by a consensus European Neuroendocrine Tumor Society (ENETS) expert group, but it requires validation. In addition, the form of peritoneal involvement (nodular or fusiform/infiltrative) might influence its prognosis and management. Aggressive surgical management seems justified for subsets of NET-related PC but requires careful selection of the candidates most likely to benefit. Cytoreductive surgery prolongs survival, especially when the peritoneal lesions are completely resected. Too little is known about the benefit of hyperthermic intraperitoneal chemotherapy for NET-derived PC, but if it confers an advantage, it would have to be counterbalanced by its high morbidity.

show abstract

Section: Evaluation Of Pcmentioning

confidence: 99%

Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors

Mestier¹,

Lardière-Deguelte

Brixi³

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…It is a valuable technique that can show the presence of peritoneal carcinomatosis or if the disease is inoperable / unresectable before cytoreductive surgery (38). Nevertheless, it should be kept in mind that this method may lead to under/overstaging of the disease (39). In patients undergoing laparoscopy, the retroperitoneum, mesenteric root, pancreatic invasion must be thoroughly evaluated with preoperative CT.…”

Section: Discussionmentioning

confidence: 99%

Cytoreductive surgery (SRC) for treatment of peritoneal carcinomatosis and hyperthermic ıntraperitoneal chemotherapy (HIPEC): Our initial experience and technical details

Topgül

Çetinkaya

Arslan

et al. 2015

UCD

View full text Add to dashboard Cite

Objective: The aim of this study is to present our initial experience in peritoneal carcinomatosis treatment and the technical details of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the light of current literature. Material and Methods:Data of 27 consecutive patients who were treated with CRS and HIPEC for peritoneal carcinomatosis in Medical Park Samsun Hospital, between November 2012 and September 2014 were retrospectively reviewed. Treatment indication and management were evaluated at the multidisciplinary oncology council. All patients underwent CRS and HIPEC with the aim of complete cytoreduction. Patients with unresectable disease and/or palliative surgery were excluded from analysis. Perioperative complications were classified according to Clavien-Dindo classification, and HIPEC-related side effects were identified using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) criteria. Demographic, clinical and histopathological data of the patients were analyzed. Results:The mean age was 54 (32-72). Nineteen patients were female. The origin of peritoneal carcinomatosis was colorectal cancer in 12 patients, ovarian cancer in 12 patients, gastric cancer in 2 patients and pseudomyxoma peritonei in 1 patient. The mean Peritoneal Carcinomatosis Index was 12 (3-32), with a mean operative time of 420 (300-660) minutes. Perioperative morbidity, HIPEC-related toxicity and perioperative mortality were observed in eight (30%), one (3.7%) and four patients (14.8%), respectively. During a mean follow up of 13 (1-22) months, overall and disease-free survival rates were 95.8% and 82.6%, respectively. Two patients with colorectal cancer (after 9 and 12 months) and one patient with ovarian cancer (after 11 months) had intra-abdominal recurrence. One patient with ovarian cancer had liver metastases 13 months after surgery, and underwent resection of segments 6-7. The remaining patients are being followed-up without any recurrence. Conclusion:Cytoreductive surgery and HIPEC have favorable results in the treatment of patients with peritoneal carcinomatosis. Compatible with the literature, surgical outcomes of the presented series are encouraging for this treatment modality that have been recently popularized in our country. Careful perioperative evaluation, proper patient selection and multidisciplinary approach are essential for success in curative treatment of peritoneal carcinomatosis.

show abstract

“…Laparoscopic exploration has been proposed as a complementary method for predicting PCI in patients selected for CRS plus HIPEC [43]. Because a clear underestimation of the laparoscopic PCI score compared with open PCI has been shown [44,45], a more defined clinical and radiological selection process is necessary to understand which patients are eligible for pre-CRS plus HIPEC laparoscopy workup. This would avoid unnecessary laparotomy in a higher percentage of cases and contribute to a more cost-effective treatment and better QoL for these patients.…”

Section: Peritoneal Diffusionmentioning

confidence: 99%

Peritoneal Carcinomatosis from Colorectal Cancer

Sommariva

Rossi²

2015

Treatment of Peritoneal Surface Malignancies

View full text Add to dashboard Cite

Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis

Abstract: Diagnostic laparoscopy was valuable in preoperative evaluation of the extent of peritoneal carcinomatosis, and improved patient selection for cytoreductive surgery and HIPEC.

Cited by 122 publications

References 21 publications

Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors

Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors

Cytoreductive surgery (SRC) for treatment of peritoneal carcinomatosis and hyperthermic ıntraperitoneal chemotherapy (HIPEC): Our initial experience and technical details

Peritoneal Carcinomatosis from Colorectal Cancer

Contact Info

Product

Resources

About